Scarica l'app Stockscreener
2.66
0.00%
0.00
Dopo l'orario di chiusura:
2.63
-0.03
-1.13%
Precedente Chiudi:
$2.66
Aprire:
$2.73
Volume 24 ore:
304.42K
Relative Volume:
0.06
Capitalizzazione di mercato:
$24.63M
Reddito:
$2.09M
Utile/perdita netta:
$-30.04M
Rapporto P/E:
-0.8138
EPS:
-3.2685
Flusso di cassa netto:
$-27.57M
1 W Prestazione:
-4.66%
1M Prestazione:
-23.78%
6M Prestazione:
-55.67%
1 anno Prestazione:
-70.38%
Intervallo 1D:
$2.59
$2.84
Intervallo di 1 settimana:
$2.59
$2.9399
Portata 52W:
$2.13
$13.13
Cervomed Inc Stock (CRVO) Company Profile
Nome
Cervomed Inc
Settore
Industria
Telefono
(617) 744-4400
Indirizzo
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
2.66 | 24.63M | 2.09M | -30.04M | -27.57M | -3.2685 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-13 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | Downgrade | D. Boral Capital | Buy → Hold |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-12-05 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-18 | Iniziato | Chardan Capital Markets | Buy |
| 2024-07-26 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-15 | Iniziato | Canaccord Genuity | Buy |
| 2020-11-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cervomed Inc Borsa (CRVO) Ultime notizie
CervoMed Inc (CRVO) Cash Flow - TradingKey
CervoMed Inc (CRVO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CRVO|CervoMed Inc|Price:2.690|Chg%:+0.030 - TradingKey
CRVO|CervoMed Inc|Price:2.640|Chg%:-0.020 - TradingKey
CervoMed Inc (CRVO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CervoMed Inc (CRVO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
CervoMed Inc. Revenue Breakdown – NASDAQ:CRVO - TradingView
CRVO|CervoMed Inc|Price:2.660|Chg%:-0.010 - TradingKey
Matt Winton Says Most Biotechs Are Not the Best to Launch Their Own Drugs — and That’s a Strength, Not a Failure - finance.biggo.com
Insiders the Biggest Winners as CervoMed Inc.'s (NASDAQ:CRVO) Market Cap Rises to US$151m - 富途牛牛
H.C. Wainwright reiterates CervoMed stock rating at buy, $25 target - Investing.com UK
H.C. Wainwright reiterates CervoMed stock rating at buy, $25 target By Investing.com - Investing.com South Africa
CRVO Reiterated by HC Wainwright & Co. -- Rating Maintained at B - GuruFocus
H.C. Wainwright Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $25 - Moomoo
CervoMed Inc. Announces New Clinical Data for Neflamapimod in Dementia with Lewy Bodies at AAIC 2026 - Minichart
CervoMed (NASDAQ: CRVO) highlights DLB trial data and Phase 3 plans - Stock Titan
CervoMed selects 50 mg Phase 3 dose - grafa.com
CervoMed presents dementia drug data at AAIC 2026 conference By Investing.com - Investing.com Nigeria
CervoMed Inc. Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in Treatment of Dementia with Lewy Bodies - marketscreener.com
CervoMed presents dementia drug data at AAIC 2026 conference - Investing.com
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) - The Manila Times
CervoMed Announces New Clinical, Plasma Biomarker and - GlobeNewswire
H.C. Wainwright reiterates CervoMed stock rating on trial enrollment - Investing.com UK
H.C. Wainwright reiterates CervoMed stock rating on trial enrollment By Investing.com - Investing.com Australia
CRVO Reiterates Buy Rating by HC Wainwright -- Price Target Main - GuruFocus
CervoMed Inc. SEC Filing (Jul 13, 2026) - Stock Titan
CervoMed (NASDAQ: CRVO) registers 10,081,131 private placement shares for resale - Stock Titan
CervoMed Completes Phase 2 Enrollment of Neflamapimod for Frontotemporal Dementia; Interim Data Accepted at CTAD Conference 9 – Minichart - Minichart
CervoMed completes enrollment in Phase 2a nfvPPA trial; interim biomarker data slated for CTAD - TradingView
CervoMed (NASDAQ: CRVO) finishes Phase 2a nfvPPA enrollment and schedules CTAD data - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
CervoMed finalizes Phase 2a enrollment for nfvPPA frontotemporal dementia - grafa.com
CervoMed (CRVO) Completes Enrollment in Phase 2a Study for nfvPP - GuruFocus
CRVO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
H.C. Wainwright reiterates Buy on CervoMed stock, $25 target By Investing.com - Investing.com South Africa
CervoMed completes enrollment in phase 2a nfvPPA trial By Investing.com - Investing.com South Africa
CervoMed Completes Enrollment in Phase 2a Study of Neflamapimod in Frontotemporal Dementia - Moomoo
CervoMed completes enrollment in phase 2a nfvPPA trial - Investing.com
H.C. Wainwright reiterates Buy on CervoMed stock, $25 target - Investing.com India
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia - The Manila Times
CervoMed finishes Phase 2 study in rare dementia with no U.S. or EU treatment - Stock Titan
CRVO Q1 2026 Earnings: EPS Miss Highlights Ongoing Pre-Revenue R&D InvestmentEBITDA Margin Trends - dars.gov.et
Morgan Stanley Ceases >5% Beneficial Ownership in CervoMed (NASDAQ: CRVO) - Stock Titan
CervoMed Q1 2026 Earnings: EPS Misses Estimates, Stock Rallies 1.46% Amid Pipeline ProgressEarnings Stability Report - dars.gov.et
Cash flow from operating activities of CervoMed Inc. – DUS:DP8 - TradingView
CervoMed files prospectus for offer and resale of 10.08M shares - scanx.trade
Form S-3 CervoMed Inc For: 6 July By Investing.com - Investing.com Nigeria
CRVO Set to Offer 10.08 Million Shares for Sale - GuruFocus
[S-3] CervoMed Inc. Shelf Registration Statement - Stock Titan
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026 - The Manila Times
Cervomed Inc Azioni (CRVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):